Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Interventions: CARv3-TEAM-E T cells; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Binge Eating
Interventions: Behavioral Weight Loss, Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy, Placebo, Sibutramine/Orlistat; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Knee Osteoarthritis
Interventions: Physical Therapy; Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: Not listed
Enrollment: 18 participants
Timeline: 2018
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Contraception, Ovulation
Interventions: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spiritual Care, Advanced Cancer
Interventions: Peace Intervention, Usual Care; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus
Interventions: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200); Drug · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Uncomplicated Bacterial Cystitis
Interventions: Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days, ciprofloxacin 250 mg BID x 3 days; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hereditary Angioedema
Interventions: C1 inhibitor (human) [C1 INH]; Biological
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more

Conditions: HIV
Interventions: Peer Navigator Intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer Patients, Survivor Patients, Cancer Pain
Interventions: Topical herbal plaster; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Smoking Cessation
Interventions: rimonabant; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoarthritis, Insomnia
Interventions: Placebo, Eszopiclone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Inflammatory Breast Carcinoma
Interventions: 89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Interventions: Pembrolizumab; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Visual Acuity
Interventions: ACUVUE Oasys 1-Day, Habitual Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 9
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 6 more

Conditions: SLE
Interventions: Envudeucitinib, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 48
States / cities: Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more

Conditions: Total Knee Arthroplasty (Postoperative Pain), Total Hip Arthroplasty (Postoperative Pain)
Interventions: Transcranial Direct Current Stimulation, Cognitive-Behavioral (CB) intervention; Device · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Bowel Preparation for Colonoscopy
Interventions: lubiprostone, placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Schizophrenia
Interventions: Risperidone ISM® 100 mg; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Search by objective public record fields.

CARv3-TEAM-E T Cells in Glioblastoma

Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Influence of Manual Physical Therapy on Habitual Activity in Knee Osteoarthritis

Ovulation Incidence in Oral Contraceptive Users

A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM

A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Insomnia and Osteoarthritis Study

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Effects of tDCS Combined With CBI on Postsurgical Pain

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

Comparative Bioavailability of Risperidone